Novel anti-cancer reagents capable of combating various types of tumors continue to be major research focus in many leading pharmaceutical companies round the globe. To this end, the present invention discloses processes for preparing a novel series of histidinylated cationic amphiphiles of formula I. The findings described herein also demonstrate that compounds of the present invention possess anti-proliferative activity such as anti” cancer activity and are useful in combating various types of cancer. The pharmaceutically active composition of cationic amphiphiles disclosed herein show enhanced cellular apoptosis through the Bax & Bcl-2 mediated signal transduction pathway. Cationic amphiphiles with histidine head-groups described in the present invention are likely to find future applications in the field of anti-cancer therapy.
